Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
2. Applicant’s amendment filed on 09/03/2026 is acknowledged.
3. Claims 1-11 and 21-28 are pending.
4. Applicant’s election without traverse of a method species recite in the reply filed on 09/03/2026 is acknowledged. Upon further consideration the Examiner has extended the search to the full scope of the claims.
5. Claims 1-11 and 21-28 are under consideration for their full scope.
6. Applicant’s IDS documents filed on 06/21/2022, 02/09/2024 and 01/02/2025 have been considered.
7. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
8. Claims 1-11 and 21-28 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-20 of U.S. Patent No. 12,642,849 (PTO-892; Reference A). Although the claims at issue are not identical, they are not patentably distinct from each other because claims 1-20 of U.S. Patent No. 12,642,849 are directed to a method of treating peanut allergy in a subject allergic or intolerant to peanut allergen, the method comprising administering a peanut allergen to said subject by an oral immunotherapy regimen comprising a dose escalation phase comprising a rush phase and a buildup phase, wherein during the dose escalation phase the peanut allergen is administered in a dose which is increased in increments from an initial dose of peanut allergen equivalent to up to 5 mg peanut protein, to a dose of peanut allergen equivalent to at least 400 mg peanut protein, within 6 to 10 weeks from administration of the initial dose of peanut allergen, wherein in the rush phase, the peanut allergen is administered in a dose which is increased in increments from the initial dose to a dose of the allergen equivalent of at least 12 mg peanut protein within 1 hour to 1 day from administration of the initial dose, and wherein the subject has not received an anti-IgE antibody prior to administration of the initial dose of peanut allergen and does not receive an anti-IgE antibody during the dose escalation phase of claim 1; wherein during said dose escalation phase the dose of peanut allergen is increased in increments to a dose of peanut allergen equivalent to at least 800 mg peanut protein within 8 to 13 weeks from administration of the initial dose of claim 2; wherein the dose escalation phase comprises a series of roughly doubling dose increments from the initial dose of peanut allergen to the dose of at least 400 mg or 800 mg of claim 3; wherein the dose escalation phase is 8 to 24 weeks and a final dose is reached at the end of the dose escalation phase of claim 4; wherein a final dose is reached at the end of the dose escalation phase and said treatment further comprises a maintenance phase following completion of the dose escalation phase, in which the peanut allergen is administered at a set maintenance dose which is + 10% of the final dose reached at the end of the dose escalation phase, wherein (i) the maintenance dose is the peanut allergen equivalent of at least 400 mg peanut protein, and (ii) the duration of the maintenance phase is at least 2 weeks following the completion of the dose escalation phase of claim 5; wherein: the peanut allergen dose is administered every day during the buildup phase of claim 6; wherein: the peanut allergen dose is administered every day during the maintenance phase of claim 7; wherein the rush phase is completed in 1to 12 hours from administration of the initial dose of claim 8; wherein (i) the peanut allergen is, or is present in, or derived from, a peanut protein, (ii) the peanut allergen is provided as peanut protein, as peanut flour or a defatted form thereof, (iii) the peanut allergen is provided as one or more isolated peanut allergens selected from the group consisting of Ara hi, Ara h2, Ara h3, Ara h5, Ara h6, Ara h7, Ara h8, Ara h9, Ara h10, Ara hi1, Ara h12, Ara h13, Ara hl4, Ara h15, Ara h16 and Ara h17 or a modified form of any one or more thereof, or (iv) the peanut allergen is provided as Ara h2 or a modified form thereof of claim 9; wherein the peanut allergen is administered in or on apple sauce, pudding, yoghurt or chocolate of claim 10; wherein the subject is: (i) an adult; (ii) less than 18 years old; (iii) less than 10 years old; (iv) less than 5 or 6 years old; (v) from 1 month to 12 years old; (vi) from 6 to 12 years old; or (vii) from 1 to 5 years old of claim 11; wherein a reduced duration of dose escalation phase compared to oral immunotherapy regimens using a longer dose escalation phase to reach a same maintenance dose improves the likelihood or odds of the subject achieving sustained unresponsiveness of claim 12; wherein during said dose escalation phase the dose of peanut allergen is increased in increments to a dose of peanut allergen equivalent to at least 2 g peanut protein within 16 to 24 weeks from administration of the initial dose of claim 13; wherein a final dose is reached at the end of the dose escalation phase and said treatment further comprises a maintenance phase following completion of the dose escalation phase, in which the peanut allergen is administered at a set maintenance dose which is + 10% of the final dose reached at the end of the dose escalation phase, wherein: (i) the maintenance dose is the peanut allergen equivalent of at least 800 mg peanut protein, and (ii) the duration of the maintenance phase is at least 26 weeks following the completion of the dose escalation phase of claim 14; wherein a final dose is reached at the end of the dose escalation phase and said treatment further comprises a maintenance phase following completion of the dose escalation phase, in which the peanut allergen is administered at a set maintenance dose which is + 10% of the final dose reached at the end of the dose escalation phase, wherein: (i) the maintenance dose is the peanut allergen equivalent of at least 2000 mg peanut protein, and (ii) the duration of the maintenance phase is at least 60 weeks following the completion of the dose escalation phase of claim 15; wherein the peanut allergen dose is administered every 2 or 3 days during the buildup phase of claim 16; wherein the peanut allergen dose is administered every 2 or 3 days during the maintenance phase of claim 17; wherein using a dose escalation phase of 8 to 12 weeks to reach a maintenance dose of 400 mg or more improves the likelihood or odds of the subject achieving sustained unresponsiveness compared to oral immunotherapy regimens using a longer dose escalation phase to reach the same maintenance dose of claim 18; wherein using a dose escalation phase of 8 to 14 weeks to reach a maintenance dose of 800 mg or more improves the likelihood or odds of the subject achieving sustained unresponsiveness compared to oral immunotherapy regimens using a longer dose escalation phase to reach the same maintenance dose of claim 19; and wherein using a dose escalation phase of 16 to 24 weeks to reach a maintenance dose of 2000 mg or more improves the likelihood or odds of the subject achieving sustained unresponsiveness compared to oral immunotherapy regimens using a longer dose escalation phase to reach the same maintenance dose of claim 20.
The reference teachings anticipate the claimed invention.
9. No claim is allowed.
10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to NORA MAUREEN ROONEY whose telephone number is (571)272-9937. The examiner can normally be reached on M-F from 8:00am to 4:30pm.
If attempts to reach the examiner by telephone are unsuccessful, the examiner' s supervisor, Misook Yu, can be reached at telephone number (571) 272-0839. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from Patent Center. Status information for published applications may be obtained from Patent Center. Status information for unpublished applications is available through Patent Center for authorized users only. Should you have questions about access to Patent Center, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) Form at https://www.uspto.gov/patents/uspto-automated- interview-request-air-form.
September 30, 2026
/Nora M Rooney/
Primary Examiner, Art Unit 1641